Stocks analysis

ABBV vs ADSK Stock Comparison

Scores Breakdown

Metric ABBV ADSK
📈 Growth 15/30 28/30
💰 Profitability 16/20 18/20
🏦 Financial Health 12/20 12/20
💵 Valuation 12/20 12/20
⚠️ Risk (lower is better) 6/10 5/10
Overall Score 59/100 75/100

Side-by-Side Summaries

ABBV Analysis ADSK Analysis

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

  • Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
  • Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from roughly $1.50B to $1.93B, and Net Income grew from about $275M to $491M, delivering a clear top‑ and bottom‑line uptrend. The sequence shows steady sequential gains with only modest quarterly volatility, translating to ~29% revenue growth and ~78% net income growth across the period.

💰 Margins & Cash Flow

Gross margins run in the mid‑to‑high 80s percent range, with Gross Profit margin staying strong relative to Revenues. Operating leverage appears favorable as operating income remains healthy while R&D and other investments persist. Cash flow from operations is consistently positive, often in the hundreds of millions (e.g., ~$460–$564M), with occasional financing outflows; investing cash flow is modest and generally supportive of ongoing growth.

🛡️ Balance Sheet & Liquidity

Total assets hover around $9.5–11B and long‑term debt sits near $2.3–2.5B, yielding a balance sheet with solid equity (around $2.5–3.1B). Current liabilities and assets are balanced enough to sustain operations, providing resilience through moderate liquidity headroom.

⚠️ Key Drivers & Risks

  • Drivers: AI-enabled design features and expanding cloud adoption.
  • Risks: Valuation sensitivity to multiples and near‑term liquidity headroom pressures from financing activities.